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Abstract
Background: Measurements of plasma and urinary catecholamine are susceptible to confounding factors that influence the
results, complicating the interpretation of sympathetic nervous system (SNS) activity in the Obstructive sleep apnea (OSA)
and arterial hypertension (HYP) conditions.
Objective: In this study, we validated a test for platelet catecholamine and compared the catecholamine levels (adrenaline
and noradrenaline) in urine, plasma and platelets in patients with OSA and HYP compared with controls.
Methods: In the validation, 30 healthy, nonsmoking volunteers who were not currently undergoing treatment or
medication were selected as the control group. One hundred fifty-four individuals (114 OSA, 40 non-OSA) were
consecutively selected from the outpatient clinic of the Sleep Institute and underwent clinical, polysomnographic and
laboratory evaluation, including the urinary, plasma and platelet levels of adrenaline (AD) and noradrenaline (NA). Patients
were then allocated to groups according to the presence of OSA and/or hypertension.
Results: A logistic regression model, controlled for age and BMI, showed that urinary AD and urinary NA were risk factors in
the OSA+HYP group and the HYP group; however, the model showed higher levels of platelet NA for OSA without HYP.
After 1 year of CPAP (continuous upper airway pressure) treatment, patients (n = 9) presented lower levels of urinary NA
(p = 0.04) and platelet NA (p = 0.05).
Conclusion: Urinary NA and AD levels were significantly associated with the condition of hypertension with and without
OSA, whereas platelet NA with OSA without comorbidity. These findings suggest that platelet catecholamine levels might
reflect nocturnal sympathetic activation in OSA patients without hypertension.
Citation: Feres MC, Cintra FD, Rizzi CF, Mello-Fujita L, Lino de Souza AA, et al. (2014) Evaluation and Validation of a Method for Determining Platelet
Catecholamine in Patients with Obstructive Sleep Apnea and Arterial Hypertension. PLoS ONE 9(6): e98407. doi:10.1371/journal.pone.0098407
Editor: Joseph Najbauer, University of Pe´cs Medical School, Hungary
Received December 4, 2013; Accepted May 2, 2014; Published June 9, 2014
Copyright:  2014 Feres et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by fellowships from Fundac¸a˜o de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), and from Associac¸a˜o Fundo de
Pesquisa a Psicobiologia (AFIP), Brazil. Dr. Dalva Poyares and Sergio Tufik are the recipients of the CNPQ grants. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: marcia.feres@unifesp.br
Introduction
Measurement of catecholamine concentrations are requested
often for the monitoring of many diseases, especially hypertension
and pheochromocytoma [1,2]. There is also a growing interest in
obstructive sleep apnea (OSA) and its consequences [3–6]. Among
these consequences, arterial hypertension (HYP) has been widely
investigated [7–9]. In a recent update the authors reported the
links between; hypertension, resistant hypertension and OSA [10].
Repetitive collapse of the upper airways during sleep, which
may lead to arousal, hypoxemia, hypercapnia, and hemodynamic
changes, contributes to increases in sympathetic tonus in OSA
patients [11,12]. The accumulation of sympathetic bouts during
sleep following apnea events results in an increase in peripheral
vascular resistance [13]. One of the most relevant candidates for
the development of daytime HYP in OSA patients is chronic
sympathetic activation [14–17]. Less attention has been paid to
other mechanisms [18–21].
Plasma and urinary noradrenaline (NA) and adrenaline (AD)
are frequently used in clinical settings to assess sympathetic status.
However, these methods have limitations, which include unstable
catecholamine levels, venous puncture influence, the effects of
exercise and others [22–24]. In addition, their half-lives are short,
which may preclude a more accurate estimation of their levels,
particularly in OSA patients whose catecholamine levels may only
be elevated during sleep [22,23]. This may explain the controversy
found in the literature when NA and AD levels are investigated in
OSA patients [24]. In this context, Zweifler & Julius [25] argue
that platelets constantly accumulate plasma-dependent catechol-
amine. While a plasma catecholamine levels fluctuate significantly,
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platelet catecholamine does not, and remain unchanged for 72
hours on average. This stability of catecholamine levels in platelets
may facilitate its detection in patients with OSA, whose levels are
mainly increased during sleep.
Coy et al., [22] published a meta-analysis and observed similar
difficulties due to an absence of standardized criteria for the
assessment of monoamines. In addition, some studies have failed
to control for confounding factors [22,23]. Only 39% of studies
controlled for dietary factors despite their documented influence
on sympathetic nervous system (SNS) physiology. Increases in
dietary sodium and carbohydrate levels have also been shown to
affect catecholamine levels [20]. Obesity and hypertension are
associated with high sympathetic tone and are also associated with
OSA; both are major confounders when assessing sympathetic
activity and catecholamine levels in OSA patients [7,20,23].
The objectives of this controlled study were to compare two
different catecholamine laboratory tests, high pressure liquid
chromatography (HPLC) and radioimmunoassay (RIA), and to
validate and evaluate the platelet NA and AD assessment
compared with urine and plasma tests in patients with OSA and
hypertension.
The first experiment aimed to validate the methodology for
measuring catecholamine levels in platelets and plasma of
volunteers. Studies which assessed platelet catecholamine used
HPLC technique. Most commercially RIA kits for adrenaline and
noradrenaline are available to measure plasma and urine levels
[26]. Therefore, we found important to validate platelet catechol-
amine dosage using both techniques RIA and HPLC comparing
their performance with plasma, as a first step.
The second study compared OSA and HYP groups with regard
to the NA and AD in urine, plasma and platelet tests. We also
compared all catecholamine detection methods, in a subgroup of
OSA patients, before and after CPAP (Continuous Positive Airway
Pressure), the gold standard treatment for OSA [27].
We hypothesized that platelet catecholamine dosage is a better
method to detect catecholamine elevation in OSA patients whose
noradrenaline and adrenaline levels are mainly increased during
sleep.
Methods
Experiment 1 – Validation
For this experiment 30 healthy, non-smoking volunteers (14
men), aged 18 to 55 years old (mean age 51.367.9) with mean
BMI = 27.863.8 kg/m2 were evaluated. The volunteers were not
under any medical treatment. Twenty ml of blood was obtained in
EDTA with anticoagulant and plasmatic and platelet catechol-
amine levels were measured using both RIA and HPLC.
Experiment 2 – Effect of OSA and HYP on catecholamine
levels
A total of 156 subjects, from the Sleep Institute of Sao Paulo,
Brazil, were consecutively enrolled in the protocol during the
period from 2009 to 2011. They each underwent full polysomno-
graphy. Participants were included if they were aged between 30
and 65 years old (both genders), sedentary (exercise activity for at
least 30 min on fewer than 3 days per week) and reported no
recent hospitalization. The exclusion criteria were a body mass
index (BMI). 40 kg/m2, metabolic syndrome, pulmonary disease
or New York Heart Association class III or IV heart failure,
unstable angina, valvular heart disease, life-threatening arrhyth-
mia, atrial fibrillation, left bundle branch block, uncontrolled
hypertension, renal disease, use of any antiplatelet drug, pregnan-
cy and those who were receiving treatment for OSA. All of these
exclusion criteria were applied in a larger study of an OSA patient
cohort [28]. An apnea-hypopnea index (AHI) $ 5 events/hour
was considered to be diagnostic for OSA, and the control group
was comprised of subjects with an AHI, 5 events/hour. The final
sample was composed of four groups: Group I (n = 64, OSA and
HYP), Group II (n = 50, OSA), Group III (n = 16, HYP) and
Group IV (n = 24, Control). Eighty one percent of hypertensive
patients used inhibitors of angiotensin converting enzyme (ACE)
and/or hydrochlorothiazide, and 19% used beta-blockers. For
ethical reasons, hypertensive patients already medicated were
instructed to maintain their regular prescription, with the
exception of an eventual dosage the night before blood collection.
Patients were instructed not to take this nightly dose, but to wait
and take it the next day only after the collection of biological
materials.
The study was approved by the Ethics Committee of Federal
University of Sao Paulo (CEP 0053; 10) and was in compliance
with the Declaration of Helsinki II. All individuals signed the
informed consent form, a copy of which was kept in their medical
chart at Sleep Institute.
Clinical evaluation
A staff cardiologist examined all patients and control subjects.
The medical evaluation included blood pressure (for hypertension
diagnosis, according to the seventh report of the Joint National
Committee on Prevention, Detection, Evaluation and Treatment
of High Blood Pressure and anthropometric parameters [29],
weight and height measurements, and neck, waist and hip
circumferences. Lung function testing was performed following
the procedures, and the percentage of predicted values recom-
mended by the American Thoracic Society was used to exclude
pulmonary disease [30].
Polysomnography
Overnight polysomnography was performed using the digital
system EMBLA (17 channels, Natus Neurology, Ontario, Cana-
da). The following variables were monitored: electroencephalo-
gram (C3-A2, C4-A1, O1-A2, O2-A1), electroocculogram, elec-
tromyogram (submental and anterior tibialis muscles),
electrocardiogram (ECG), presence of snoring, and body position.
Chest and abdominal piezo-sensors monitored respiratory effort.
Arterial oxygen saturation (SaO2) was recorded with a pulse
oximeter. All polysomnographies were performed and scored by
an experienced sleep technician and a sleep physician following
the guidelines for sleep studies [31]. Arousals and respiratory
events [30] were defined using the standard criteria [31]. A second
full polysomnography was performed for CPAP (continuous upper
airway pressure) titration in all OSA patients,
Laboratory tests
The laboratory tests were performed in two steps. First, on the
day of clinical evaluation, participants were asked to have a twelve
hour fasting period and to come to the Sleep Clinic at 8:00 AM for
blood sample collection for hemogram, creatinine, urea, glycemia,
lipid profile, and hepatic function measures. The biochemical
profile and the hepatic function measures were performed by an
automated assay (ADVIA 1650, Siemens), and the hemogram was
performed by microscopic and automated methods (ADVIA 120,
Siemens).
One week later, participants returned to the Sleep Clinic for
determination of urinary, plasma and platelet catecholamine.
They were asked to abstain from a hypercaloric diet, alcohol,
caffeine, chocolate, carbonated beverages, and tea three days
before collection of blood and 24-hour urine [32]. Blood samples
Catecholamine and Obstructive Sleep Apnea
PLOS ONE | www.plosone.org 2 June 2014 | Volume 9 | Issue 6 | e98407
for plasma and platelet catecholamine measurements were
obtained from an antecubital vein. The samples were collected
in the morning at 9 AM, after a 12-hour fasting period and 1 hour
of rest. Twenty four hour urine was collected from participants
and then acidified with 5 mL of 6N HCl prior to the tests [33].
Preparation of blood samples
The blood samples were immediately brought to the laboratory
and prepared as described below:
Twenty milliliters of blood was collected in tubes containing
50 mL of 0.2 M NaEDTA solution per milliliter [34]. The platelet
separation technical procedure followed the procedure described
by Chamberlain et al., [34] and cited by Christensen et al., [35]
The supernatants were decanted, and platelets were frozen and
stored at 280uC until the analysis could be performed [34].
Release of catecholamine from platelet granules was assured by
the addition of 10 mL 10% Triton X-100 to each 240 mL of
platelet suspension after thawing. Otherwise, platelet suspensions
were assayed in the same way as plasma samples, and the results
are expressed relative to platelet number (pg/108) [34].
Plasma: 2.5 mL of blood was collected in tubes, as previously
described, and centrifuged for 10 min at 1800 g. The plasma was
stored at 280uC until the analysis could be performed. All tests
were performed in duplicate in each assay. Internal standards were
used with every sample, and tests were analyzed according to
reference values for each assay.
NA and AD concentrations in plasma, urine and platelets were
quantified by a sensitive and accurate radioenzymatic assay with
reagents from DIAsource Immunoassays S.A. (Nivelles, Belgium;
Genese, Sao Paulo, Brazil). All tests were performed in duplicate.
The cutoff suggested by the manufacturer of the reagents is ,
20 mg/24 hours for urinary adrenaline and , 100 pg/mL for
plasmatic adrenaline; the cutoff is , 90 mg/24 hours for urinary
noradrenaline and , 600 pg/mL for plasmatic noradrenaline. In
the present study, we estimated cutoff levels for the different
assessments, i.e., platelet, urine and plasma assessments for our
population.
OSA treatment
Of 114 patients who were offered CPAP, only nine patients
successfully completed one year of CPAP use (compliance measure
of smart card considered . 4 hours a day for at least 70% of the
time) [36]. It is relevant to mention that there is no reimbursement
for CPAP in most Brazilian states, which means that patients must
pay for the treatment costs. These 9 patients were reevaluated
after one year.
Statistical analysis
In Study 1, Pearson correlations and coefficients of variation
between and within assays (CV %) were calculated. For Study 2,
descriptive analysis was based on the comparison of the four
groups performed by ANCOVA with age, abdominal circumfer-
ence and BMI as covariates. A Spearman correlation test was used
to verify whether the three methods were comparable. We tested
whether the standardized cutoff values of the tests were associated
with clinical diagnoses of HYP and moderate or severe OSA (with
or without HYP) using receiver operating characteristic (ROC)
curves. Because cutoff values are only available for plasma and
urine measurements, we used ROC curves to adjust the standard
cutoff values for urine and plasma and to find new indicators in
platelet analysis for the clinical diagnosis of HYP and OSA (with
or without HYP).
The ROC curve was also used to obtain the sensitivity and
specificity for different cutoff points. The sensitivity and specificity
of urinary AD and NA (UAD and UNA), plasmatic AD and NA
(PLAD and PLNA), and platelet AD and NA (PTAD and PTNA)
measures for the detection of HYP and OSA, as well as their odds
ratio and the calculation of the area under the curve (AUC) were
analyzed. Finally, confidence intervals of catecholamine levels
were calculated using the bootstrapping method to maximize the
accuracy of measurement for each clinical condition, i.e., OSA
and HYP.
Based on the new cutoff points found for each clinical condition,
binary logistic regressions (controlled for BMI and age) were
carried out to test this new measurement. The following
independent variables were considered: biochemical measures of
platelet in the different groups (OSA and HYP), and only OSA or
HYP.
The sample size and Power analysis was calculated using
GPower software version 3.1.2 (2009). With a priori expected
effect size of 15% for differences among groups, observed Power
approximately 80% and significance level 5% (p,0.05), our
minimum sample size is 102 participants. By avoiding missing data
and drop-outs during the study, we increased our data by 50%,
yielding an actual sample of 154 participants. The analyses were
conducted using ‘‘R’’ version 2.10.0 (R Development Core Team,
2009).
Results
Experiment 1
The measurements of AD and NA in platelets by RIA and
HPLC were compared. Figure 1 shows correlation results of both
measures. Significant correlations were found between plasma
RIA and HPLC for both AD and NA (r = 0.82 and r = 0.77,
respectively). Similar results were obtained for AD and NA platelet
assays, (r = 0.93 and r = 0.92). Due to good correlation results
between NA and AD RIA and HPLC, RIA was chosen, based on
the Westgard J. protocol [37] (Figure 1).
The coefficients of variation (CV) for AD and NA plasma were
significantly higher than the platelet CVs. Adrenaline results:
(plasma CV = 35612.3% and platelet CV = 2569.5%). Nor-
adrenaline results: (plasma CV = 2869.4% and platelet
CV = 23617.2%). In the light of these validation results we
performed RIA in experiment 2.
Experiment 2
The sample consisted of 156 individuals (91 women and 65
men) with a mean age of 50.867.9 years and an average BMI of
27.663.6 kg/m2.
We excluded two volunteers who did not complete the blood
collection, as well as one volunteer who had exerted physical effort
the day before blood sampling. The general characteristics of the
groups’ mean of anthropometric, polysomnographic and labora-
tory measures, including the catecholamine levels of the study
sample, are shown in Table 1.
We observed that the groups showed significant differences with
respect to age (p ,0.05): Group IV (control) was younger
(44.366.5 years) than groups I, II and III (55.567.2, 49.566.7
and 50.266.2 years). BMI was also statistically significant
(p = 0.0008) between groups I, II, and III (29.963.2, 28.063.3
and 28.863.7 kg/m2) when compared with the control group
(25.464.1 kg/m2).
Table 1 depicts the average and standard deviations (adjusted
for age and the BMI) of the anthropometric, polysomnographic,
and laboratory catecholamine (AD and NA). Multiple compari-
sons of means were performed between groups.
Catecholamine and Obstructive Sleep Apnea
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Figure 1. Correlation tests between methods of platelets and plasmatic catecholamine dosage RIA X HPLC.
doi:10.1371/journal.pone.0098407.g001
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The groups were significantly different when the anthropomet-
ric parameter variables were compared to those of the control
group. Aside from age and BMI, neck circumference (p = 0.0009),
abdominal circumference (p = 0.0401), systolic blood pressure
(p = 0.0006) and diastolic blood pressure (p = 0.0006) all signifi-
cantly differed among groups. Regarding polysomnographic data,
significant differences were found in AHI (p = 0.0002), minimal
saturation (p = 0.022) and arousal index (p = 0.001) as expected.
The results of biochemical tests for the study groups showed that
urinary, plasma and platelet catecholamine levels were higher in
OSA with HYP, OSA, and HYP groups when compared to the
control groups; however, the results did not reach statistical
significance (Table 1). Similarly, the platelet catecholamine levels
were also higher than the urinary and plasma levels in the same
groups, but again did not reach statistical significance (Table 1).
Biochemical test results
The correlations (r) in adrenaline measurements between
methods ranged from 0.13 to 0.21, (weak and non-significant
correlations), but for UAD vs. PTAD, the correlation was
acceptable (r = 0.64, p = 0.02). The same was true for UNA vs.
PTNA measures (r = 0.60, p = 0.01).
The following results refer to the analysis of the ROC curve for
each analyte. We report the sensitivity and specificity for different
cutoff points after comparison according to the HYP, OSA and
OSA+HYP groups, as follows.
Hypertension (HYP)
The new thresholds for UAD ($ 4.21 mg/24H), UNA ($
40.0 mg/24H), PLAD ($ 25.0 pg/mL), PLNA ($ 170.0 pg/mL),
PTAD ($ 38.0 pg/108), and PTNA ($ 413.0 pg/108) are
displayed in Table 2. These results show that PLAD, PTAD and
PTNA performed better for hypertension detection after using the
new thresholds. Therefore, due to the actions of adrenaline/
noradrenaline, patients who have values above the suggested
bootstrap cutoff points are more prone to hypertension (Table 2).
A ROC curve was constructed for each platelet variable and the
best hypertension predictors were found to be PTAD with 81%
sensitivity and PTNA with 90% sensitivity, although the areas
under the curve (AUC) were moderate, ranging from 67–81%.
This was not sufficient to diagnose the HYP using the cutoffs from
the literature (Table 3).
OSA with HYP
The ROC curve showed that the best indicators for OSA with
HYP, were UAD, PLAD, PTAD and PTNA levels (p = 0.00,
p = 0.00, p = 0.00 and p = 0.01, respectively) (Table 2).
The cutoff points, proposed by the bootstrap, and their
sensitivities and specificities emphasize that PTNA (sensitivi-
ty = 72%) and PTAD (sensitivity = 75%) are not good indicators
of interaction between OSA and HYP diagnoses (Table 3).
OSA
The ROC curve showed that PLAD, PTAD, UNA, PLNA and
PTNA levels were significant indicators for detecting OSA alone
(p = 0.01, p = 0.02, p = 0.03, p = 0.00 and p = 0.00, respectively).
The sensitivity of diagnostic tests for OSA detection ranged from
67.0% for PLAD to 85.0% for PTNA (Table 2). Considering the
cutoff points obtained by bootstrap indicators, PTAD showed 67%
sensitivity; however, PTNA showed 85% sensitivity with 73%
specificity for the diagnosis of OSA (Table 3).
Table 1. Anthropometric, clinical, polysomnographic and catecholamine data, presented as means and standard deviations and
corresponding to the baseline characteristics of the groups.
Number of cases (154)
Group I N=64
OSA+HYP Mean±SD
Group II N=50 OSA
Mean±SD
Group III N=16 HYP
Mean±SD
Group IV N=24
Control Mean±SD P
Age (Years) 55.567.2 49.566.7 50.266.2 44.366.5 0.0007*
Male gender (%) 26 16 10 13 42%
BMI (kg/m2) 29.963.2 28.063.3 28.863.7 25.464.1 0.0008*
Cervical circumference (cm) 37.060.7 36.360.7 33.662.2 31.461.1 0.0009*
Abdominal circumference (cm) 94.461.4 95.161.4 91.664.4 92.662.3 0.0401*
Hip circumference (cm) 98.663.6 100.663.6 102.0611.1 97.662.3 0.6500
Systolic arterial pressure
(mmHg)
139.662.6 131.662.6 144.768.1 129.664.3 0.0006*
Diastolic arterial pressure
(mmHg)
90.062.0 86.362.0 90.366.3 82.063.3 0.0006*
AHI (events/h) 21.363.2 22.263.2 3.263.9 5.465.2 0.0002*
Total sleep time (min) 340.6665.1 332.06106.1 267.96184.3 349.6699.6 0.2400
Minimal saturation (%) 85.661.4 83.961.5 89.064.5 89.462.4 0.0220*
Arousal index 18.463.0 23.163.1 7.369.4 14.864.9 0.0011*
UAD (mg/24H) 3.2160.72 4.1860.81 3.6461.3 3.2460.85 0.22
PLAD (pg/mL) 23.7619.4 64.0618.5 48.4659.6 16.7631.4 0.66
PTAD (pg/108platelets) 128.3686.1 115.6686.4 148.46254.0 111.46139.1 0.89
UNA (mg/24H) 41.168.4 38.564.4 40.1615.7 29.769.9 0.19
PLNA (pg/mL) 193.7679.1 299.7680.3 302.26245.1 85.16129.1 0.33
PTNA (pg/108platelets) 651,16506,7 557,76451,7 511,66528,6 381,26209,5 0,10
*Significant value (p#0.05).
doi:10.1371/journal.pone.0098407.t001
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Logistic regression results
In Table 4, a binary logistic regression model was created where
each measure was defined as a continuous independent variable,
after which the capacity of continuous measurements to discrim-
inate between each group (OSA+HYP, OSA and HYP) was
verified. This was performed as a complementary analysis because
it is a model that helps identify the factors that influence the risk of
a clinical outcome, and it also enables the analysis of their
respective odds ratios using newer reference cutoff points
established through ROC curve analysis.
The logistic model showed that an increase of 1 unit in the
variable UAD resulted in a 1.63-fold increase in the chance of
having HYP, while a 1-unit increase in UNA increased the chance
of having HYP by 1.03-fold. Regarding OSA alone, a 1-unit
increase of PTNA increased the chance of having OSA by 1.01-
fold, whereas a 1-unit increase of UAD increased the chance of
Table 2. Results of the cutoff points obtained by the bootstrap for determination of AD and NA in different biological samples and
groups.
Variables Cutoff present % absence % OR p
HYP group
UAD $ 4.21 9 5 1.8 p = 0.09
(mg/24 h) 64.2%, 35.8%
PLAD $ 25.0 14 22 1.4 p = 0.03*
(pg/ml) 33.7% 56.3%
PTAD $ 38.0 13 32 1.6 p = 0.01*
(pg/108platelets) 28.8 71.2
UNA $ 40.0 6 18 1.7 p = 0.05*
(mg/24 h) 56.0% 42.0%
PLNA $ 170.0 9 15 1.4 p = 0.30
(pg/ml) 41.0% 59.0%
PTNA $ 413.0 18 24 1.3 p = 0.03*
(pg/108platelets) 52.0% 46.0%
OSA + HYP group
UAD $ 4.21 26 48 1.5 p = 0.00*
(mg/24 h) 55.0% 45.0%
PLAD $ 25.0 24 18 1.3 p = 0.00*
(pg/ml) 57.0% 43.0%
PTAD $ 38.0 49 18 2.7 p = 0.00*
(pg/108platelets) 60.0% 40.0%
UNA $ 40.0 25 17 1.4 p = 0.62
(mg/24 h) 40.0% 60.0%
PLNA $ 170.0 32 45 1.3 p = 0.18
(pg/ml) 52.0% 48.0%
PTNA $ 413.0 43 21 1.8 p = 0.01*
(pg/108platelets) 57.0% 43.0%
OSA group
UAD $ 4.21 23 27 1.2 p = 0.65
(mg/24 h) 45.0% 55.0%
PLAD $ 25.0 50 12 4.1 p = 0.01*
(pg/ml) 40.0% 60.0%
PTAD $ 38.0 42 25 1.7 p = 0.02*
(pg/108platelets) 32.0% 68.0%
UNA $ 40.0 19 31 1.8 p = 0.03*
(mg/24 h) 42.0% 68.0%
PLNA $ 170.0 32 18 1.7 p = 0.00*
(pg/ml) 48.0% 62.0%
PTNA $ 413.0 28 45 1.4 p = 0.00*
(pg/108platelets) 65.0% 35.0%
*Significant value (p#0.05).
doi:10.1371/journal.pone.0098407.t002
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having OSA with HYP by 1.55-fold. Finally, a 1-unit increase in
UNA increased the chance of having OSA and HYP by 1.01-fold.
Table 4 showed that UAD and UNA were the best predictors
for HYP alone, with p = 0.01 and p = 0.03, respectively. Regard-
ing OSA without HYP, only PTNA showed significance (p = 0.03)
as a marker for identifying OSA. UAD and UNA were the best
associated factors for OSA with HYP (p = 0.00 and p = 0.01,
respectively).
Group with one year of treatment with CPAP
Nine patients (3 female, 6 male) successfully completed one year
of daily CPAP use. Their mean CPAP pressure was 1063 cm
H2O. Patients mean age was 56.065.2, mean AHI of 37.065.0,
and they were all hypertensive.
When baseline values and those obtained after one-year of
CPAP treatment were compared by a Wilcoxon test, we found
significant decreases only for UNA (78.24611.23 vs. 68.17614.8;
T = 9.0, Z = 1.59, p = 0.04) and PTNA (691.80671.13 vs.
429.60668.71; T = 7.0, Z = 1.83, p = 0.05) (Table 5).
Discussion
Studying the catecholamine detection through laboratory
measurements is a challenge due to confounding factors that
influence the results of measuring urinary and plasmatic levels
[38]. In addition, the physical and chemical properties of these
neurotransmitters necessitate a careful choice of assessment
methodology [39].
In the literature, there are several studies that assessed the SNS
by determining catecholamine concentrations. Different tech-
niques have been adopted, and the gold standard for catechol-
amine measurement is the HPLC method along with urinary
measurement [26,38,39].
Our validation study for the platelet catecholamine method was
to compare two methodological techniques, HPLC vs. RIA, which
were not previously compared (experiment 1). The results showed
a good correlation; therefore, we decided to use the RIA method.
This method demonstrated the following advantages for this study:
more acceptable percentages (as demonstrated by the coefficients
of variation [CV%], intra and inter assay of platelet noradrenalin
and adrenalin by RIA method), a greater ease and speed of
execution, greater sensitivity and a smaller sample volume. In this
way, our results substantiated our choice of this RIA method [40].
We did not perform validation methodology for 24-hour urine,
because it is difficult to recruit volunteers to collect 24-hour urine.
The authors focused on platelet and plasma catecholamine dosage,
because platelet catecholamine concentration is dependent on the
plasma pool. We acknowledge that muscle sympathetic activity,
among all techniques, is the gold standard method to estimate
sympathetic tone [41,42]. However, is beyond the scope of this
study to compare other techniques for the sympathetic activity
assessment, other than body fluid analysis. We actually focused on
catecholamine detection and laboratorial assays.
In experiment 2, analysis of the levels of catecholamine (AD and
NA) in the three biological materials showed poor correlation
between AD and NA levels in plasma and platelets; however, the
study showed a strong correlation between urinary AD and NA
levels.
This result is consistent with expectations because the urinary
measurements reflect the overall rate of catecholamine excretion,
and the catecholamine platelets, which are dependent on the
plasma release pool, are able to retain catecholamine longer (48 to
72 hours); this is unlike plasma catecholamine, which reflects its
very short half-life. The results of our analysis showed that the
methods of measuring catecholamine levels assess catecholamine-
release differently.
Measured concentrations of urinary catecholamine metabolites
and their products can be used as markers of sympathetic tone
during urine collection [38,39,41]. In children with OSA an
overnight increase in urinary concentrations of catecholamine was
found [42]. There are many problems inherent in the evaluation
of plasma catecholamine levels, in particular as a SNS activation
index, because these concentrations show large intra-variability
that is exacerbated by factors such as venipuncture, stress, and
physical exertion. These problems, which can result in increased
variability, could be partially solved using the urinary catechol-
amine (urine, 24 h) measurement methodology. There are
accuracy problems with this collection procedure, and studies
that included analysis of intra-individual variability in catechol-
amine urinary concentrations suggest that the plasma measure-
ments are higher [39,40]. There are, however, studies in the
literature that consider urinary catecholamine levels and their
metabolites as the best parameters in OSA and HYP studies [41–
44].
Mechanisms have been proposed to explain why OSA increases
sympathetic tone. Usually sympathetic nerve activity, heart rate
and blood pressure levels decline from wakefulness to non-REM
sleep and increase again during REM sleep in normal sleepers
without OSA. Stimulation of awakening is accompanied by
increased sympathetic nerve activity, leading to transient increases
Table 3. Calculations of sensitivity, specificity and positive and negative predictive values of PTAD and PTNA.
Variables Group I OSA + HYP Group II OSA Group III HYP Group IV CONTROL
PTAD (pg/108platelets)
sensitivity 75% 67% 81% 79%
specificity 53% 73% 70% 61%
value p+ 74% 78% 83% 62%
value p- 73% 57% 72% 80%
PTNA (pg/108platelets)
sensitivity 72% 85% 90% 74%
specificity 60% 73% 70% 75%
value p+ 63% 85% 86% 85%
value p- 70% 76% 85% 74%
doi:10.1371/journal.pone.0098407.t003
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in blood pressure [43]. It is likely that over time the OSA patient
will continue to have increased sympathetic activity during the
day, or at least in the early morning hours [41]. Thus, the
significant association between HYP and OSA may be mediated
by increased SNS activity and its effectors, noradrenaline and
adrenaline, contributing to increased cardiovascular morbidity
and mortality in these patients [6–10,18].
A simple method that could detect such an increase in
sympathetic activity in patients with OSA (treated or untreated)
is of great value in clinical settings. This is the first study to
evaluate platelet catecholamine content in OSA associated with
hypertension comorbidity, a method widely used for pheochro-
mocytoma diagnosis. This method has advantages related mainly
to increased catecholamine availability in platelets, which ranges
from several minutes in plasma (half-life) to 48 hours in platelets
[43,44]. There are also no alterations associated with sudden
changes, such as stress, exercise and diet [19,20,18,44–47].
The ROC curve analysis demonstrated low sensitivity among
the methods (urine, plasma and platelet), in part because a subset
(71%) of the total number of patients with hypertension (n = 54)
was treated with medications that could potentially affect
catecholamine levels. Although 81% of hypertensive patients did
not use beta-blockers, they did use inhibitors of angiotensin
converting enzyme (ACE) and/or hydrochlorothiazide. For ethical
reasons, hypertensive patients who were already taking medica-
tions were instructed to maintain their regular prescription;
however, they were instructed to refrain from taking antihyper-
tensive medication the night before blood collection, and to only
take it after the collection of biological materials.
Because platelet catecholamine had not yet been studied in
these clinical populations, we used the bootstrap analysis to
determine cutoff points for the proposed method, increasing the
sensitivity and specificity of the method on the conditions under
study, as presented in Tables 2 and 3. We found that the bootstrap
conditions for sleep apnea and hypertension were, on average,
33% lower than the values found in the literature for the general
population. It might be explained by the fact that our sample does
not represent the general population, since it included patients
who seek treatment for their conditions. However, we can assume
that our data present high level of Interval Validity (with regard to
Homogeneity of sample), which is relevant considering the
objective of this study. Potential low External Validity can be
associated with this lower cutoff because another variables found
in our population may not be significantly present in the general
population, such as high sympathetic activation, yielding lower
cutoffs values to discriminate patients with OSA or Hypertension.
Urinary adrenaline and noradrenaline reference values were
then considered to be # 20 mg/24 h and # 90 mg/24 h,
respectively, and for plasma adrenaline and noradrenaline the
values were # 100 pg/mL and # 600 pg/mL, respectively.
Finally, because the samples were consecutively selected at the
Outpatient Sleep Institute, we were careful to statistically adjust
the variables of age and BMI in the models. The standard diet for
collection of biological material was respected and was one of the
inclusion criteria.
The main findings of this study were the differential high levels
of catecholamine in urine, platelets and plasma in the population
with associated OSA and HYP which may explain the controver-
sial results previously reported [22]. In the population with OSA
without HYP, noradrenaline in platelets (PTNA) showed a better
response. This finding demonstrates that platelets are more
sensitive in subjects with OSA who have not developed
hypertension, and who probably have increased sympathetic
activity exclusively during sleep. In hypertensive individuals
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without OSA, urinary adrenaline (UAD) and noradrenaline levels
(UNA) were more sensitive independent of medication, suggesting
that such urinary measurements may be higher in patients with
hypertension, with or without OSA. Only platelet noradrenaline,
which is synthesized in the central nervous system (not platelet
adrenaline, which is mainly synthesized at the adrenal medulla
level), was found to perform better for OSA recognition. Finally,
some studies suggest an association between OSA and platelet
aggregates and volume [48–50]. On the other hand, catechol-
amine also increase platelet aggregates increasing cardiovascular
risk [48]. Whether this association influences the catecholamine
platelet detection in OSA patients is not clear.
Interestingly, in a relatively small sample of 9 patients, after one
year of treatment with CPAP, only the urinary and platelet NA
decreased significantly, while all plasma assays and AD levels did
not show improvement with CPAP. Indeed, some studies showed
that catecholamine levels were attenuated after treatment, and
may worse after its withdrawal, suggesting that catecholamine
levels may serve as a surrogate biomarker of OSA severity and
may be used to monitor patients responses to treatment [51–53].
Potential limitations of this study were the use of an indirect
assay method (RIA), the use of a radioisotope in this method, and
the relatively small sample of OSA patients successfully treated.
Even with a small sample size for blood and urinary assays, we
were able to suggest that platelet as well as urine assays might be
superior to plasma tests in this clinical population. Future studies
with a larger sample of OSA patients and randomized trials with
CPAP are worthwhile to validate platelet catecholamine assess-
ment, particularly NA assessment, in this population, and perhaps
in resistant hypertension patients. In the clinical context,
utilization of catecholamine levels as a potential biomarker of
OSA with respect to diagnoses and therapy monitoring deserves
further validation [53].
In conclusion, we found that urinary noradrenaline and
adrenaline levels were significantly associated with the condition
of hypertension with and without OSA, whereas platelet
noradrenaline was superior in detecting OSA without comorbid-
ity. These findings suggest that in OSA, nocturnal sympathetic
activation may be better detected by a technique that increases
catecholamine availability, such as platelet dosage.
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